What is onpattro?

What is Onpattro, and what does it treat?

Onpattro is the brand name for patisiran, a medicine used for transthyretin (TTR) amyloidosis with polyneuropathy. It’s designed to help treat nerve damage caused by abnormal TTR protein deposits in people with this condition.[1]

How does Onpattro work?

Onpattro is an RNA-based therapy. It targets the production of the disease-causing TTR protein by using a mechanism that reduces TTR levels, which helps limit the formation of amyloid deposits that drive symptoms like polyneuropathy.[1]

How is Onpattro taken?

Onpattro is given as an infusion (administered through a vein), typically on a recurring schedule as directed by a clinician.[1]

Who makes Onpattro, and where can I find patent/drug-detail info?

If you’re looking for company and patent-related tracking, DrugPatentWatch.com provides a dedicated page for Onpattro/patisiran.[2]

Sources

[1] https://www.drugs.com/ppa/onpattro.html
[2] https://www.drugpatentwatch.com/p/patisiran-onpattro